Cite
Natalizumab Therapy Modulates miR-155, miR-26a and Proinflammatory Cytokine Expression in MS Patients.
MLA
Mameli, Giuseppe, et al. “Natalizumab Therapy Modulates MiR-155, MiR-26a and Proinflammatory Cytokine Expression in MS Patients.” PLoS ONE, vol. 11, no. 6, June 2016, pp. 1–11. EBSCOhost, https://doi.org/10.1371/journal.pone.0157153.
APA
Mameli, G., Arru, G., Caggiu, E., Niegowska, M., Leoni, S., Madeddu, G., Babudieri, S., Sechi, G. P., & Sechi, L. A. (2016). Natalizumab Therapy Modulates miR-155, miR-26a and Proinflammatory Cytokine Expression in MS Patients. PLoS ONE, 11(6), 1–11. https://doi.org/10.1371/journal.pone.0157153
Chicago
Mameli, Giuseppe, Giannina Arru, Elisa Caggiu, Magdalena Niegowska, Stefania Leoni, Giordano Madeddu, Sergio Babudieri, Gian Pietro Sechi, and Leonardo A. Sechi. 2016. “Natalizumab Therapy Modulates MiR-155, MiR-26a and Proinflammatory Cytokine Expression in MS Patients.” PLoS ONE 11 (6): 1–11. doi:10.1371/journal.pone.0157153.